Results 201 to 210 of about 43,190 (248)

Response to ‘Re: Kakkos et al. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials’ [PDF]

, 2014
Stavros K. Kakkos, George Kirkilesis, Ioannis A. Tsolakis   +2 more
openalex   +1 more source

PARIS coronary thrombosis risk score combined with D-dimer to guide new oral anticoagulant antithrombotic therapy in patients with acute coronary syndrome after percutaneous coronary intervention: study protocol for the PRIDE-ACS trial. [PDF]

BMJ Open
Jia S, Song Y, Yuan D, Wang P, Xu J, Chen Y, Zhang C, Zhao X, Yuan JQ.   +8 more
europepmc   +1 more source

Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non‐valvular atrial fibrillation: Results from ROCKET AF [PDF]

, 2014
Ihab Girgis, Manesh R. Patel, Gary Peters, Kenneth Todd Moore, Kenneth W. Mahaffey, Christopher C. Nessel, Jonathan L. Halperin, Robert M. Califf, Keith A.A. Fox, Richard C. Becker   +9 more
openalex   +1 more source

Challenges and Opportunities of Direct Oral Anticoagulant (DOAC) Therapy in Complex Clinical Scenarios: A Comprehensive Review and Practical Guide. [PDF]

J Clin Med
Miceli G, Ciaccio AM, Tuttolomondo A.
europepmc   +1 more source

Demographic and Socio-Economic Disparities in the Outcomes Among Patients with NVAF Treated with Oral Anticoagulants: A Real-World Evaluation of Medicare Beneficiaries. [PDF]

J Clin Med
Atreja N, Dubey A, Kohli M, Jiang J, Hagan M, Aweh G, Adams S, Cheng D.   +7 more
europepmc   +1 more source

Association of rivaroxaban plasma trough concentrations with clinical characteristics and outcomes. [PDF]

Front Pharmacol
Wu H, Yu Q, Jin P, Huo L, An J.
europepmc   +1 more source

Efficacy and safety of off-label direct oral anticoagulants vs. warfarin for left ventricular thrombus: an inverse probability of treatment weighting analysis. [PDF]

Front Cardiovasc Med
Al-Maimoony T, Al-Matari K, Al-Habeet A, Aljaber NN, Al-Marwala M, Al-Hashmi S.   +5 more
europepmc   +1 more source

Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program

, 2014
Brahim Bookhart, Lloyd Haskell, Luke Bamber, Maria Wang, Jeff Schein, Samir H. Mody   +5 more
openalex   +1 more source

Pharmacoeconomic evaluation of direct oral anticoagulants for cancer-associated thrombosis: a systematic review. [PDF]

Front Public Health
You X, Liu Y, Wang X, Qin J, Wang X.
europepmc   +1 more source

Anticoagulant prescribing trends, bleeding events, and reversal agent use in pediatric patients: A retrospective, real-world study. [PDF]

PLoS One
D'Abrantes S, Male C, Brown N, Bjursell M, Ambery P, Berggren A, Mattsson U.   +6 more
europepmc   +1 more source